The earlier phase results clearly showed the win for methylated mesenchymal patients, a small but very important indicator group that mesenchymal was responding well. With regard to this trial mesenchymal and mesenchymal transition we’re going to be a critical factor for success based on very early due diligence I did. Methylation super charges the effect but a much higher percent of methylation was found to be associated with proneural subtype which already had advantages attached but in general showed less to almost no response to L treatment. At least one of those advantages led to reclassification of GBM. Best wishes.
Market Data 
Markets 
AI
